ProQR Therapeutics N.V. - Ordinary Shares - fluxo de caixa (NASDAQ:PRQR)

Financials

Fluxo de caixa operacional —————— — Fluxo de caixa de investimento —————— — Fluxo de caixa de financiamento —————— — Fluxo de caixa livre —————— —

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

PRQR

Financials

ProQR Therapeutics N.V. - Ordinary Shares

Notícias

Citizens mantém recomendação para PRQR com potencial em atresia biliar

ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow (NASDAQ:PRQR) 2026-05-15

Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-04-08

ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

Citizens reitera classificação de compra para ProQR Therapeutics

Citizens reiterates ProQR Therapeutics stock rating on RNA editing platform potential

Lucro da ProQR Therapeutics NV superou projeções por €0,02; receita supera estimativas

ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates